Core Viewpoint - Evolent Health, Inc. plans to offer $140 million in convertible senior notes due 2031, with an option for initial purchasers to buy an additional $20 million, aimed at improving financial flexibility and supporting share repurchases [1][2]. Group 1: Offering Details - The offering consists of $140 million aggregate principal amount of convertible senior notes due 2031, subject to market conditions [1]. - Evolent expects to use up to $100 million of the net proceeds to repurchase a portion of its existing 1.50% convertible senior notes due 2025 and approximately $40 million for repurchasing shares of its Class A common stock [2]. - The notes will be convertible into cash, shares of Evolent's Class A common stock, or a combination thereof, with interest payable semiannually starting February 15, 2026 [4]. Group 2: Repurchase Strategy - Evolent plans to repurchase shares of its Class A common stock sold short by initial investors at a price equal to the last reported sale price on the pricing date, which may influence the market price of the stock [3]. - The company anticipates that holders of the 2025 Notes who agree to have their notes repurchased may unwind their hedges by buying Evolent's Class A common stock, potentially affecting the stock price [6]. Group 3: Conversion Rights - The conversion rights of the notes may be terminated by Evolent on or after August 20, 2026, under specific conditions related to the stock price performance [5]. - The conversion price and other terms of the notes will be determined at the time of the offering's pricing [4]. Group 4: Regulatory Information - The notes and any Class A common stock issued upon conversion will not be registered under the Securities Act, and may only be offered to qualified institutional buyers [7]. - The press release does not constitute an offer to sell or a solicitation to buy the securities described [8]. Group 5: Company Overview - Evolent Health specializes in improving health outcomes for individuals with complex conditions, serving a national base of leading payers and providers [9].

Core Viewpoint - Simmons First National Corporation has announced a public offering of 16,220,000 shares of its Class A common stock at a price of $18.50 per share, totaling approximately $300 million [1][2]. Group 1: Offering Details - The public offering is priced at $18.50 per share, with an aggregate offering amount of $300,070,000 [1]. - The company has granted underwriters a 30-day option to purchase an additional 2,433,000 shares at the public offering price [1]. - The offering is expected to close on or about July 23, 2025, subject to customary conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, which may include investments in Simmons Bank to support potential balance sheet repositioning and continued growth [2]. Group 3: Company Background - Simmons First National Corporation is a financial holding company based in the Mid-South, with a history of paying cash dividends for 116 consecutive years [6]. - Its principal subsidiary, Simmons Bank, operates over 220 branches across several states, including Arkansas, Kansas, Missouri, Oklahoma, Tennessee, and Texas [6]. - Simmons Bank has received multiple recognitions, including being named one of America's Best Regional Banks 2025 by Newsweek [6].